PB2307: PHARMACOKINETICS, EFFICACY AND SAFETY OF SUBCUTANEOUS VERSUS INTRAVENOUS RITUXIMAB COMBINED WITH CHOP IN CHINESE PATIENTS WITH UNTREATED CD20-POSITIVE DIFFUSE LARGE B CELL LYMPHOMA: A RANDOMIZED TRIAL

PB2307: PHARMACOKINETICS, EFFICACY AND SAFETY OF SUBCUTANEOUS VERSUS INTRAVENOUS RITUXIMAB COMBINED WITH CHOP IN CHINESE PATIENTS WITH UNTREATED CD20-POSITIVE DIFFUSE LARGE B CELL LYMPHOMA: A RANDOMIZED TRIAL

Bibliographic Details
Main Authors:	Yan Gao, Liling Zhang, Sujun Gao, Yu Yang, Qing-Yuan Zhang, Huilai Zhang, Pengcheng He, Fei LI, Hongmei Jing, Susan Grange, Lilian Bu, Qianming Wang, Yanjie Wang, Huiqiang Huang
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000975952.54634.fd

Similar Items

2307
by: Joey Annette Contreras, et al.
Published: (2017-09-01)

Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
by: Delgado Sánchez O, et al.
Published: (2019-11-01)

Evaluating the benefits of transitioning from intravenous to subcutaneous Rituximab for Alberta cancer patients
by: Cherie Severson
Published: (2015-07-01)

Review of T-2307, an Investigational Agent That Causes Collapse of Fungal Mitochondrial Membrane Potential
by: Nathan P. Wiederhold
Published: (2021-02-01)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
by: Koh Ki-Ryang, et al.
Published: (2009-08-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

The Arylamidine T-2307 as a Novel Treatment for the Prevention and Eradication of <i>Candida tropicalis</i> Biofilms
by: Angela Maione, et al.
Published: (2022-12-01)

P1171: REFLECT: PROSPECTIVE NON-INTERVENTIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF SANDOZ RITUXIMAB (SDZ-RTX) WITH CHOP FOR PATIENTS WITH PREVIOUSLY UNTREATED CD20-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
by: M. Welslau, et al.
Published: (2022-06-01)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
by: Giulia Bega, et al.
Published: (2021-12-01)

PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3)
by: Benoit Tessoulin, et al.
Published: (2023-08-01)

P1224: EFFICACY OF RITUXIMAB AND BIOSIMILAR RITUXIMAB IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, A DANISH POPULATION BASED ANALYSIS
by: A. Haujir, et al.
Published: (2022-06-01)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
by: Vít Procházka, et al.
Published: (2020-07-01)

Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial
by: Jun Zhu, et al.
Published: (2022-11-01)

P1186: RETROSPECTIVE STUDY: ZANUBRUTINIB COMBINED WITH R-CHOP OR R-CHOP REGIMEN IN THE TREATMENT OF UNTREATED NON-GERMINAL CENTER B-CELL SUBTYPE DIFFUSE LARGE B-CELL LYMPHOMA WITH EXTRANODAL INVOLVEMENT.
by: LI Caixia, et al.
Published: (2023-08-01)

Results of the randomised phase II NCRI arctic (attenuated dose rituximab with chemotherapy in CLL) trial of low dose rituximab in previously untreated CLL
by: Munir, T, et al.
Published: (2014)

REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon) in combination with CHOP for the treatment of patients with previously untreated CD20-positive diffuse large B-cell lymphoma
by: Manfred Welslau, et al.
Published: (2023-06-01)

P1196: ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL
by: Chang-Ju Qu, et al.
Published: (2023-08-01)

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
by: William Townsend, et al.
Published: (2023-07-01)

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
by: Michael Herold, et al.
Published: (2022-03-01)

Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
by: Carsten Hirt, et al.
Published: (2021-07-01)

Treatment of Indolent Cutaneous B-Cell Lymphoma with Intralesional or Intravenous Rituximab
by: Christian Menzer, et al.
Published: (2022-09-01)

P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL
by: Yan Gao, et al.
Published: (2023-08-01)

Long-term survival after fludarabine, cyclophosphamide, and rituximab treatment in previously untreated chronic lymphocytic leukemia patients
by: Shokhan Mohammad Mustafa, et al.
Published: (2021-01-01)

Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration
by: Juan Sebastián Galecio, et al.
Published: (2020-08-01)

Comparing the Effect of Subcutaneous and Intravenous Tramadol Injection on Postoperative Pain
by: Hamid Hajigholam Hajigholam Saryazdi, et al.
Published: (2011-03-01)

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey
by: Ponzetti C, et al.
Published: (2016-05-01)

Correction Notice: Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
Published: (2022-06-01)

PB2307: A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ROMIPLOSTIM PLUS DEXAMETHASONE VS DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA
by: M. E. Mingot Castellano, et al.
Published: (2022-06-01)

Comparison of “Nagahara Phaco-Chop” and “Stop-And-Chop Phacoemulsification Techniques”
by: Devrim Toslak, et al.
Published: (2018-07-01)

The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy
by: Bjorkander, J, et al.
Published: (2000)

Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing
by: Federico Argüelles-Arias, et al.
Published: (2023-08-01)

Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
by: Patrice Cacoub, et al.
Published: (2023-04-01)

A randomized controlled trial to assess safety and efficacy between terminal chop, stop and chop, and direct chop
by: Aprajita Sinha, et al.
Published: (2023-01-01)

PB2084: FIRST-LINE TREATMENT IN ADVANCED STAGE FOLICULAR LYMPHOMA: A SINGLE-CENTER EXPERIENCE WITH R-CHOP VS BENDAMUSTINE-RITUXIMAB.
by: O. Mompel, et al.
Published: (2022-06-01)

PB2097: ZANUBRUTINIB PLUS RITUXIMAB FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE-B CELL LYMPHOMA
by: J.-F. Bai, et al.
Published: (2022-06-01)

Availability of chop‐chop in Victorian tobacconists following introduction of plain packaging
by: Michelle Scollo, et al.
Published: (2014-06-01)

Design and Experiment of Profiling Furrow-Ridge Terrain by Cane Leaf-Chopping and Returning Machine
by: Biao Zhang, et al.
Published: (2024-03-01)

Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a systematic literature review and meta-analysis
by: Tianyu Si, et al.
Published: (2023-12-01)

Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience
by: Murat Özbalak, et al.
Published: (2022-11-01)